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Abstract
Background: Artemisinin-based combination treatment (ACT) has been widely adopted as one of the main malaria
control strategies. However, its promise to save thousands of lives in sub-Saharan Africa depends on how effective the
use of ACT is within the routine health system. The INESS platform evaluated effective coverage of ACT in several
African countries. Timely access within 24 hours to an authorized ACT outlet is one of the determinants of effective
coverage and was assessed for artemether-lumefantrine (Alu), in two district health systems in rural Tanzania.
Methods: From October 2009 to June 2011we conducted continuous rolling household surveys in the Kilombero-Ulanga
and the Rufiji Health and Demographic Surveillance Sites (HDSS). Surveys were linked to the routine HDSS update rounds.
Members of randomly pre-selected households that had experienced a fever episode in the previous two weeks were
eligible for a structured interview. Data on individual treatment seeking, access to treatment, timing, source of treatment
and household costs per episode were collected. Data are presented on timely access from a total of 2,112 interviews in
relation to demographics, seasonality, and socio economic status.
Results: In Kilombero-Ulanga, 41.8% (CI: 36.6–45.1) and in Rufiji 36.8% (33.7–40.1) of fever cases had access to an
authorized ACT provider within 24 hours of fever onset. In neither of the HDSS site was age, sex, socio-economic status or
seasonality of malaria found to be significantly correlated with timely access.
Conclusion: Timely access to authorized ACT providers is below 50% despite interventions intended to improve access
such as social marketing and accreditation of private dispensing outlets. To improve prompt diagnosis and treatment,
access remains a major bottle neck and new more innovative interventions are needed to raise effective coverage of
malaria treatment in Tanzania.
Background
Following high investment in the fight against malaria, very
important progress has been made for its control across
Africa, including Tanzania [1-8]. However, the disease still
remains an important public health problem in the country
and accounts for nearly one third of the country’s disease
and mortality burden [9]. Children under five years of age
and pregnant women are at highest risk of the disease and
its subsequent adverse outcomes. Even though, as the
overall burden is decreasing, the burden is shifting towards
older children and young adults [10].
Prompt recognition and timely treatment with efficacious
drugs remains a primary control strategy for malaria [11].
Artemisinin-based combination therapy (ACT) has been
recommended as the drug of choice for the treatment of
uncomplicated malaria and have widely been adopted as
first line treatment in sub-Saharan Africa [12]. Early
diagnosis and treatment are crucial in achieving the drug’s
intended benefits. Proliferating malaria parasites which are
responsible for life-threatening malaria complications and
fostering transmission can be rapidly and effectively
controlled if effective treatments are taken within 24h of
onset of clinical signs and symptoms [13]. Several studies
have demonstrated an association between delayed treat-
ment and appreciable level of malaria mortality [14-16].
Therefore, timely access to an authorized outlet of ACT
within 24 h is one determinant of effective coverage. To
reduce the malaria mortality by 50%, the Roll Back Malaria
partnership has set a target of 80% for timely access [17].
The Malaria Eradication (malERA) Consultative Group on
Health Systems and Operational Research has introduced
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the systems effectiveness decay framework [18] that has
defined effective coverage in terms of conditional probabil-
ities of population access, accurate targeting, provider
compliant delivery and patient adherence. While malaria
elimination and eradication are on top of the global agenda,
correct and effective treatment is one of the main drivers
towards the prerequisite of malaria control.
Tanzania was one of the first groups of countries to
implement health systems studies using the systems effect-
iveness framework to evaluate ACT in the routine health
system. Separate modules were used for assessing each
dimension of the framework (access, diagnostic targeting,
provider compliance and patient adherence). This paper
presents results on timely access of fever patients to autho-
rized ACT treatment outlets. Further work on other
dimensions will be published separately.
Since 2007, artemether-lumefantrine is the first line treat-
ment for uncomplicated malaria in Tanzania [19,20]. The
drug is dispensed in officially-authorized treatment outlets
which include government and non-governmental hospi-
tals, health centres, dispensaries, pharmacies and private
but accredited drug dispensing outlets (ADDOs). ADDOs
are small privately operated retail outlets in rural and peri-
urban communities in Tanzania. These outlets whose staff
are trained by the government are licensed to sell a set list
of essential medicines, including selected prescription
drugs, such as ACT. It is a strategy that was intended to
expand access to treatments for some common illnesses
such as malaria. It was rolled out throughout the country
in phased form since 2007. This study compares areas with
and without ADDOs.
Methods
Study area and population
Data for this study were collected within the framework of
the Rufiji and Kilombero-Ulanga HDSS sites. Both sites are
located in the Greater Rufiji River Basin in southern
Tanzania. The sites are primarily rural with majority of the
population relying on subsistence farming or fishing. Both
sites are characterized by heavy rains from March to May.
Rufiji
Villages constituting Rufiji HDSS site are situated in Rufiji
District, Coast Region and cover a total of 16,685 house-
holds and 84,095 residents in 38 villages. The villagers be-
long to varied ethnic groups, the biggest being Ndengereko,
Matumbi, Nyagatwa and Ngindo. Islam is the dominant
religion in the area.
Kilombero-Ulanga
Kilombero-Ulanga HDSS includes 28,000 households with
a total population of 120,000 in 25 villages in the districts
of Kilombero and Ulanga. The main ethnic groups are
Ndamba, Pogoro and Hehe. The population is equally
divided between Christians and Muslims.
During the time of our survey there were 24 health
facilities and a limited number of ADDOs in Rufiji HDSS
and there were 14 health facilities and 44 ADDOs in KU.
In Rufiji, the population level of malaria parasitaemia is
15% and in KU 13% [7]. In both sites, malaria was historic-
ally intense [21-27]. Important progress has been made in
its control, and population parasitaemia levels have fallen
from 26% in 2001 to 15% in 2006 in Rufiji and from 18% to
13% over the same period in KU [7], yet the disease still
remains one of the key public health problems. However,
malaria transmission in the districts is still endemic, most
common from June to September, the period after the long
rain season.
Fever has been used as the defining indicator of malaria
and every fever has long been treated as malaria in the area
as it for the rest of the country. Health facility based studies
have of late demonstrated a significant decline of malaria
parasitaemia among febrile patients in health facilities. Only
33% of fever patients were diagnosed with malaria using
malaria Rapid Diagnostic Tests (RDT) from this district’s
health facilities [28]. Existing observations suggest malaria
parasitaemia among patients with fever complaints in
health facilities was 20% in this site [28]. However, intermit-
tent RDT stock-outs and continuing treatment of malaria
without parasitological confirmation mean that ACT con-
tinues be used in the majority of fever cases.
Sample size and sample size calculation
Sample size was calculated based on the assumption of 50%
of the fever cases seek and gain access, an annual fever
prevalence of 6%, a design effect of 1.5 to account for
clustering within households, and a dropout rate of 10%.
To estimate the proportion of patients that gain access to
an ACT provider within 24/48 hours after onset of fever
with a precision ±5%, a minimum of 1,152 interviews
needed to be conducted in each site.
Procedures
In each HDSS household an interview was conducted as
part of the routine HDSS update rounds. From October
2009 to June 2011 a total of 4,648 and 4,226 households
were randomly pre-selected from the Rufiji and KU
household registers respectively. In each HDSS the survey
was conducted continuously and longitudinally, sampling
covering pre-selected households without replacement over
one calendar year to capture periods of higher and lower
malaria transmission. During HDSS site routine household
visits, each member was asked if they had fever or malaria
in the preceding 14 days. If yes, they were eligible for the
in-depth interview after written informed consent was
obtained. For children under 12 years approval was
obtained from their parents or guardians. The interview
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was conducted at household level. Data on individual
treatment-seeking, access to treatment, services sought,
drugs provided, and associated household cost details for
all costs associated with the episode were captured. Field
workers carried photo albums with views of all possible
malaria treatment packaging in order to identify drugs
provided. The socio-economic status of each household
was obtained from the asset surveys from the HDSS.
Ethical approval
Ethics approval for the study was granted by the institu-
tional review boards of Ifakara Health Institute (IHI), and
by the National Tanzanian Medical Research Co-ordinating
Committee of the National Institute for Medical Research
(NIMR).
Data analysis
Data were entered using EpiData (Odense, Denmark) and
transferred into STATA version 10 software (Stata Corp,
College Station, TX) for merging, cleaning and performing
analyses. The main outcome measure was the proportion
of fever patients that sought treatment from an authorized
ACT provider within 24 hours of fever onset. Secondary
outcomes evaluated were: a) the proportion of fever
patients that sought treatment from an authorized ACT
provider within forty eight hours of the onset of fever; and
b) the proportion of malaria patients that sought treatment
from an authorized ACT provider after forty eight hours of
the onset of fever. Comparison of these outcomes within
and between the two study sites was made using Chi-
square test. Logistic regression was used to assess the
importance of the selected determinants explored in the
study. The Concentration Index formula by Kakwani et al.
[29] was used to generate concentration indices from the
study to identify existence of socio-economic inequality in
24 hour access to ACT outlets.
Results
Description of the sample
A total of 1,041 and 1,103 interviews were conducted in
Rufiji and Kilombero-Ulanga HDSS sites, respectively. The
sample composition was almost equally divided between
sexes and people of different socio-economic categories
(Table 1). Over two thirds of study participants were over
five years old. As expected, the majority of fever/malaria
episodes were identified during high malaria transmission
season from both HDSS sites. The study sites are character-
ized by endemic malaria transmission with high seasonal
variation, and as shown in Table 1, over 60% of interviews
from both Rufiji and Kilombero-Ulanga were conducted
during high malaria transmission season. Health facility
visits on occurrence of fever/malaria were most common in
both sites, ranging from 47% in KU to 48% in Rufiji. Visits
to unauthorized malaria treatment outlets were more
common in Rufiji (40.5%) than in Kilombero-Ulanga
(14.7%). These unauthorized outlets were predominantly
normal shops and street kiosks. There were patients who
reported treatment visits to both health facilities and
ADDOs; 4.2% were observed in Rufiji and 5% in
Kilombero-Ulanga. Equally important, not more than 35%
of patients from Rufiji and around 19% from Kilombero-
Ulanga reported being diagnosed using either RDTs or
microscopy.
As shown in Table 2, timely access to an authorized
ACT provider was 37% (CI:33.7–40.1) in Rufiji DHSS and
42% (36.6–45.1) in Kilombero-Ulanga. Statistically signifi-
cant difference was observed in access within 48 hours
between the two sites; higher from Kilombero-Ulanga 70%
(CI:67.3–73.3) compared to Rufiji 53% (CI:49.9–56.7).
Proportion of patients with access after 48 hours was
small and there was no statistically significant difference
between the sites. The combined access within 48 hours
for the two study sites (calculated from the data but not
shown in the figure) was 62%.
Distribution of access to ACT providers within 24 hours
by malaria transmission season, sex, age groups and socio-
economic status is highlighted in Table 3. No difference
was observed between males and females from both sites.
Under-fives from both sites benefited better than the rest of
the population, however, this variation did not reach
statistical significance in either study area. In terms of
socio-economic status, no evidence of inequality between
quintiles and access to malaria treatment providers within
24 hours was proven from both sites. Concentration Index
measured from Rufiji was 1.78 (CI:–0.01–3.57). The index
from KU was 1.49 (CI: 0.01–2.99). Timely access was
shown to be the same for patients between high and low
malaria transmission seasons from both sites.
Table 4 summarizes the results in predictors for timely
access. Factors that were considered in the model were sex,
age group, type of treatment providers, wealth quintile, sex
of caretakers and seasonality in malaria transmission. The
model was adjusted to account for any potential con-
founders. There were no statistically significant differences
by sex of patient, age groups, socio-economic status, sex of
caretaker or malaria transmission season from both study
sites. There was 38% and 34% more likelihood in seeking
ACT within 24 hours from ADDOs health facilities in Rufiji
and KU respectively but differences were not statistically
significant. No difference was observed in both sites for
access within 24 hours between health facilities and other
providers. Overall, having access within 24 hours from
unauthorized providers was less likely compared to health
facilities in both sites.
Discussion
ACT has been recommended as a life-saving intervention
for malaria cases especially in sub-Saharan African
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countries which claims more than 60% of the global
malaria morbidity [30,31]. However, full benefits cannot
materialize until important health system elements,
including patients’ access, are addressed. It is argued that
malaria elimination, an essential step towards the long-
term goal of eradication, can only be achieved when a high
proportion of patients with malaria have access to effective
treatment [31]. This is critical for the malaria eradication
agenda. As is the case for many other endemic sub-
Saharan African countries, malaria is generally on the
decline in Tanzania [1-8]. However, a new push is required
to sustain the gains and move towards malaria elimin-
ation. It is in this way that this bottleneck needs urgent
attention if the potential of ACT is to be optimized and
this control agenda is to be fulfilled. It is unfortunate for
malaria control initiatives that when substantial resources
are being invested in the development and procurement
of efficacious drugs, these tools do not reach the patients
in a timely way that would contribute to malaria reduction
commensurate with their demonstrated capacity. ACT is
most effective against malaria when acting on parasites in
cases not yet severely complicated [13].
This is one of few studies that have demonstrated
patients’ access to ACT within the context of system effect-
iveness framework [25,26] in two neighbouring HDSS sites
located in three districts in Tanzania. Although the results
are not representative of the country composed of more
Table 1 Charateristics of study population in Rufiji and Kilombero-Ulanga (KU) HDSS sites, Tanzania
Rufiji KU
Number of peopple identified with recent fever 1041 (100%) 1103 (100%)
Number of people with recent fever who completed access interviews 1024 (98.4%) 1088 (98.6%)
Number of people with recent fever with incomplete access interviews 4 (0.4%) 15 (1.4%)
Number of people with recent fever with no access interviews 13 (1.3%) 0
Of those with complete interiviews
Sex
Males 442 (43.2%) 466 (42.8%)
Females 582 (56.8%) 622 (57.2%)
Age groups
Under-five children 328 (32%) 300 (27.6%)
Five years and above 696 (68%) 788 (72.4%)
Socio-economic status by asset index
Poorest 194 (19%) 176 (16.2%)
Less poor 201 (19.6%) 244 (22.4%)
Middle 192 (18.8%) 196 (18%)
More rich 229 (22.4%) 204 (18.8%)
Least poor 208 (20.3%) 268 (24.6%)
Complete interviews conducted during:
High malaria transmission season 618 (60.4%) 736 (67.7%)
Low malaria transmission season 406 (39.7%) 352 (32.4%)
Use of different malaria treatment providers
Health facilities 498 (48.6%) 511 (47%)
Accreditted Drugs Dispensing Outlets (ADDOS) 97 (9.5%) 395 (36.3%)
Other authorized treatment providers 14 (1.4%) 22 (2%)
Unauthorized providers 415 (40.5%) 160 (14.7%)
Both health facilities and ADDOs 43 (4.2%) 54 (5%)
Having a blood diagnosed using mRDT or microscopy 332 (32.4%) 199 (18.3%)
Table 2 Fever/malaria patients' access to authorized
malaria treatment providers in Rufiji and KU
Rufiji (N=1024) KU (N=1088)
n (%) 95% CI n (%) 95% CI
Access to authorized
providers within 24 h
377(36.8) 33.7-40.1 455(41.8) 38.6-45.1
Access to authorized
providers within 48 h
546(53.3) 49.9-56.7 766(70.4) 67.3-73.3
Access to authorized
providers after 48 h
205(20) 17.5-22.8 200(18.4) 16.0-21.0
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than 130 districts, they offer an insight on the health
system’s performance and an estimate of timely access to
ACT. As they are HDSS sites, their populations are investi-
gated more often and several health system interventions
were implemented on a research basis than elsewhere in
the country [7,18,21,22,27,28]. Hence it is reasonable to
estimate that these study results should not be worse than
the rest of Tanzania. The country’s latest Tanzania HIV/
AIDS and malaria indicator survey (2011-2012) was a
nationwide study, the results of which suggest 21% access
to malaria treatment within 24h [32]. Observations from
this study and those reported from TDHS 2011 fall short of
Table 3 Distribution of access within 24 h by sex, age, SES and seasonality in Rufiji and KU
Rufiji (N=1024) KU (N=1088)
n (%) 95% CI n (%) 95% CI
Distribution by seasonality
High malaria transmission season 235/618(38.0) 34.0-42.3 323/736(43.9) 39.9-47.9
Low malaria transmission season 142/406(35.0) 30.1-40.1 132/352(37.5) 32.3-43.0
Males 167/442(37.8) 33.1-42.7 196/466(42.1 37.4-46.9
Females 210/582(36.1) 32.1-40.2 259/622(41.6) 37.5-45.9
Distribution by age groups
Under-five children 134/328(40.9) 35.5-46.4 139/300(46.3) 40.4-52.3
Five years and above 243/696(34.9) 31.2-38.9 316/788(40.1) 36.4-43.9
Distribution by socio-economic status
Poorest 64/194(33.0) 26.5-40.2 66/176(37.5) 28.7-47.2
Less poor 73/201(36.3) 29.1-44.2 88/244(36.1) 30.2-42.4
Middle 63/192(32.8) 26.5-39.9 97/196(49.5) 42.1-56.9
More rich 79/229(34.5) 28.1-41.5 88/204(43.1) 36.0-50.6
Least poor 98/208(47.1) 40.0-54.4 116/268(43.3) 37.1-49.7
Concentration Index 1.78 -0.01-3.57 1.49 -0.01-2.99
Table 4 Predictors of patients' access to authorized malaria treatment providers within 24 hours in Rufiji and KU
Variable Rufiji Kilombero-Ulanga
n/N(%) Adjusted odds ratio (95%CI) n/N(%) Adjusted odds ratio (95%CI)
Male 167/442(37.8) reference 196/466(42.1) reference
Female 210/582(36.1) 0.991(0.7-1.3) 259/622(41.6) 1.063(0.8-1.4)
<5 years 134/328(40.9) reference 139/300(46.3) reference
≥5 years 243/696(34.9) 1.1(0.7-1.5) 316/788(40.1) 0.739(0.5-1.1)
Health facilities 251/550(45.6) reference 216/495(43.6) reference
ADDO 48/91(52.8) 1.383(0.9-2.2) 206/409(50.4) 1.343(1.0-1.8)
Other private 31/50(62.0) 1.886(1.0-3.6) 28/55(59.9) 1.510(0.8-2.7)
Non authorized providers 47/333(14.1) 0.230(0.2-0.5) 5/129(3.9) 0.090(0.3-0.2)
Poorest 64/194(33.0) reference 66/176(37.5) reference
Less poor 73/201(36.3) 1.24(0.8-2.0) 88/244(36.1) 0.831(0.5-1.4)
Middle 63/192(32.8) 0.92(0.6-1.4) 97/196(49.5) 1.352(0.8-2.3)
More rich 79/229(34.5) 0.987(0.6-1.5) 88/204(43.1) 1.041(0.6-1.7)
Least poor 98/208(47.1) 1.669(1.1-2.6) 116/268(43.2) 1.112(0.7-1.8)
Patients themselves 136/438(31.1) reference 189/482(39.2) reference
Male caretaker 43/108(39.8) 1.417(0.9-2.3) 65/140(46.4) 1.066(0.7-1.6)
Female caretaker 198/478(41.4) 1.433(1.0-2.1) 201/466(43.1) 1.093(0.8-1.5)
Low malaria transmission season 142/406(35.0) reference 132/352(37.5) reference
High malaria transmission season 235/618(38.0) 1.204(0.0.9-1.6) 323/736(43.9) 1.345(0.1-1.8)
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80% target set by Roll Back Malaria for achieving the poten-
tial public health benefits of ACT [33]. They suggest that
more than half of people ill with malaria in Tanzania do
not have timely access to quality ACT and are exposed to
risk of poor outcomes of the disease. These results are
comparable to the rest of rural Africa where malaria trans-
mission is endemic where a similar picture of malaria
patients’ access to ACT has been reported in Burkina Faso
and Kenya [30,34].
Fever patients’ access to ACT has long been investigated
in KU [17], following its implementation of the Access
Programme from 2004 to 2007 [23], which involved social
marketing campaigns that stressed the importance of
prompt and effective treatment for malaria. The KU site
was also among the first districts in the country having
ADDOs. There were 44 ADDOs in the study area at the
time of our survey giving an outlet to population ratio of
0.4 per 1,000. Rufiji was characterized by four ADDOs as
the study was in progress with an outlets to population
ratio of 0.05 per 1,000. Hence, both social marketing and
ADDOs should have increased timely access to appropriate
treatment in KU compared with Rufiji but we did not
detect a significant difference. This could be interpreted
that these interventions did not have an impact on fever
patients’ timely access to ACT although access after
24 hours was better in KU.
Timely access to ACT previously observed in KU from
the ACCESS programme was above 60% [17]. This is better
than the rate reported in the present study. This discrep-
ancy would be explained in two ways. One, it would be
associated with different dimensions used to report effective
coverage between our surveys and study conducted during
the ACCESS project. Alba et al. presented actual anti-
malarial drug taken by patients within 24 h following fever
episode as reported by patients or by their caretakers.
Patients would take drugs available at home or from a
neighbour or friend and this has been reported in several
studies [15,31,35,36]. Wider availability of sulphadoxine-
pyrimethamine (SP) and older drugs during ACCESS
survey was reported from KU [37]. Thirty percent and 16%
of patients self-treated at home from Rufiji and Kilombero-
Ulanga respectively from our study (data not shown in the
results section). In this study, results presented reflect
patient or caretaker reported visit made to ACT providers
within 24 h on the onset of fever illness. As reported in the
preceding sections, results on which this paper is based
have been generated from just one access dimension of
effective coverage. Other components proposed in the
effectiveness framework (targeting accuracy, prescribers’
compliance and patients’ adherence) [18] have been
conducted using different designs whose results are pub-
lished separately [28]. Findings from these papers will dem-
onstrate whether the patients obtained and used the
medicines comparable to ACCESS publications. On the
other hand, the social marketing campaigns and ADDOs
roll out might have improved timely treatment access for
fever as demonstrated in surveys that monitored their
effects. And there would be marked difference in timely
access between the intervention and comparator site. How-
ever, it is also possible that these effects were not sustained
over time.
The study has shown more than 15 percentage points
statistically significant difference in 48 h patient access
between KU and Rufiji sites. The larger ACT outlets popu-
lation ratio associated with roll out of ADDOs in KU
compared to Rufiji could be singled out as an important
reason for this difference. It would imply that after the
introduction of ADDOs patients have become closer to
treatment providers and their number making treatment
outlets visits has increased but many of them have not yet
started seeking care within 24 h. People still keep delaying
to seek treatment from appropriate providers. Observations
from some other studies conducted in one of these study
areas has suggested an association in this delay with initial
actions taken at home with anti-pyretic and locally available
anti-malarial medicines [38].
A logistic regression model was run to determine
whether there was an association in the observed access
with any factors usually estimated as risks for low patients’
access to malaria treatment. This form of analysis assumes
that risks of exposure to malaria especially in high endem-
icity areas and chances for treatment-seeking are not
normally distributed [39]. The burden is concentrated in
the poorest quintile of the population whose composition is
dominated by small children, women and those living in
remote rural communities. Hence, malaria control inter-
ventions can achieve intensive and broader effectiveness if
their coverage is equally clustered around these groups
highest at malaria transmission in high burden countries
[40]. The risks of inherent effectiveness decay on the poor
highlighted in the equity effectiveness loop framework
would be addressed when this is properly handled [41].
This study has not been able to prove whether this is hap-
pening. Women, under-fives and the poorest of the poor
were shown to have almost similar access to ACT providers
within 24 hours of malaria onset (Table 4). However, the
study cannot claim definite lack of difference in timely
access to treatment outlets in these communities by age
group or gender as it was not powered to test this. Never-
theless, in a study among the very poor in Tanzania based
on observations made in the same area, Schellenberg et al.
demonstrated unequal access to appropriate treatment
between the poorest and the least poor in that area [25].
This difference could have been addressed by subsequent
implementation of interventions that used pro-poor
approaches [19,42], such as rolling out of ADDOs, and it
might also have happened because many public health
interventions were implemented in the area generating
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duplicative effect that has extended to every population
group. As was stated earlier, Kilombero-Ulanga and Rufiji
HDSS sites were a testing ground for many public health
intervention studies in Africa. However, the only condition
that the study was powered to demonstrate was access
within 24 hours according to malaria transmission season.
This study’s exploration of patients’ access to ACT
providers was based on an assumption that fever could be a
robust indicator of malaria. Fever has actually been an entry
point for several studies seeking to understand treatment-
seeking practices for malaria including patients’ access to
treatment providers. This has been the case because
the widespread adoption of Integrated Management of
Childhood Illnesses (IMCI) that encouraged treatment of
every fever episode as malaria at a time when malaria trans-
mission was so endemic in Africa and the likelihood of
being infected with malaria parasites, especially for small
children, was so high. Challenges posed by diagnostic
technology in existence at the time and the need to treat
patients as timely as possible to prevent progression of the
disease into severe form was an important argument raised
to justify IMCI strategy. However, as malaria transmission
decreases across sub-Saharan Africa, it has been demon-
strated that the presence of rapid diagnostic tests is making
IMCI no longer an attractive strategy for malaria. Fevers
are now increasingly associated with other diseases than
malaria, including bacterial infections and especially
pneumonia [38,43]. Hence, an assumption that all fevers
are malaria is becoming increasingly inappropriate.
Conclusion
This study showed that access to point of delivery of quality
ACT, within 24 h and 48 h is significantly less than 45%
and 75% respectively. This is well short of national and glo-
bal targets despite these being relatively high performing,
highly studied districts likely to be better than average in
Tanzania. This is not a favourable development in malaria
control for the country that is still considered to be high
burden. Achieving potential impact associated with ACT,
which is essential for progress towards existing malaria
control goals, requires the intervention’s universal coverage.
It was shown that malaria was falling in Tanzania and the
country was moving in the right direction. However, as
access to ACT is still low, it would imply that malaria
decline is slower than it could be if the drug’s potential was
optimized through effective coverage.
In this study, there was no important difference between
a district having ADDOs plus social marketing to improve
24 h access to ACT outlets compared to one without. The
introduction of ADDOs in KU improved treatment outlets
population ratio. However, this development did not trans-
late into higher 24 h access to ACT outlets in KU. There
were, however, 48 h access difference between KU and
Rufiji and would likely be associated with difference in
outlets population ratio. Hence, there is a need for better
and more innovative strategies to improve timely access to
ACT in Tanzania.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RAK contributed to the design of the study, coordinated the study, performed
the statistical analyses and interpreted the data, and wrote the manuscript in
consultation with the other authors. MBS, MHN and DK performed the statistical
analyses and contributed to interpretation of the data and to the drafting and
editing of the manuscript. IMM, GAM and MA supervised the survey and
contributed to the analysis and interpretation of the data and to the drafting and
editing of the manuscript. DdS, IK and SMA conceived of the study and oversaw
all aspects of the study, including design and execution of the field work, analysis
and interpretation of the data, drafting and editing of the manuscript. All authors
read and approved the final manuscript.
Acknowledgements
This study was an integral component of a multi-country project that undertook
Phase IV effectiveness and safety studies (INESS) of new combination therapies
for malaria in seven INDEPTH Demographic Surveillance System (DSS) sites in
four countries of Africa. These sites and their respective countries are Dodowa,
Kintampo and Navrongo from Ghana; Kilombero-Ulanga and Rufiji from Tanzania;
Maniςa from Mozambique and Nouna from Burkina Faso. INESS is funded in part
by the Bill and Melinda Gates Foundation. The authors wish to thank the many
investigators, data collectors and field supervisors who contributed to the
collection and analyses of these data including: Liberati Kahumba, Steven
Magwaja, Iddi Mkilalu, Benard Mumba, Brown Kigahe, Sigbert Mrema, Mathew
Alexender, Lucas Lyoko, Fausta Lipingu. We would also acknowledge very
important contribution of Professor Fred Binka, Dr Hassan Mshinda, Dr Aziza
Mwisongo and Rahima Dossa. Finally, we wish to acknowledge the community
members who participated in or otherwise contributed to these studies.
This manuscript is published with permission from Dr. Mwele Malecela,
Director-General, National Institute for Medical Research. This study was
funded by the INDEPTH Network, Accra, Ghana.
Author details
1Ifakara Health Institute, Dar es Salaam, Tanzania. 2Swiss Tropical and Public
Health Institute, Basel 4002, Switzerland. 3University of Basel, Basel 4001,
Switzerland. 4INDEPTH Network Effectiveness and Safety Studies of
Antimalarial in Africa (INESS), Accra, Ghana.
Received: 5 December 2012 Accepted: 30 April 2013
Published: 7 May 2013
References
1. Bhattarai A, Ali AS, Kachur SP, Martensson A, Abbas AK, Khatib R, Al-Mafazy AW,
Ramsan M, Rotllant G, Gerstenmaier JF, Molteni F, Abdulla S, Montgomery SM,
Kaneko A, Bjorkman A: Impact of artemisinin-based combination therapy
and insecticide-treated nets on malaria burden in Zanzibar.
PLoS Med 2007, 4:e309.
2. Prudhomme O’Meara W, Nekesa Mangeni J, Steketee R, B G: Changes in the
burden of malaria in sub-Sahara Africa. Lancet Infect Dis 2010, 10:545–555.
3. Okiro EA, Hay SI, Gikandi PW, Sharif SK, Noor AM, Peshu N, Marsh K: The
decline in paediatric malaria admissions on the coast of Kenya. Malar J
2007, 6:151.
4. Mmbando BP, Vestergaard LS, Kitua AY, Lemnge MM, Theander TG, Lusingu JP:
A progressive declining in the burden of malaria in north-eastern Tanzania.
Malar J 2010, 9:216.
5. Barnes KI, Chanda P, Ab Barnabas G: Impact of the large-scale deployment
of artemether/lumefantrine on the malaria disease burden in Africa:
case studies of South Africa, Zambia and Ethiopia.
Malar J 2009, 8:S8.
6. Otten M, Aregawi M, Were W, Karema C, Medin A, Bekele W, Jima D, Gausi K,
Komatsu R, Korenromp E, Low-Beer D, Grabowsky M: Initial evidence
of reduction of malaria cases and deaths in Rwanda and Ethiopia
due to rapid scale-up of malaria prevention and treatment.
Malar J 2009, 8:14.
Khatib et al. Malaria Journal 2013, 12:155 Page 7 of 8
http://www.malariajournal.com/content/12/1/155
7. Khatib R, Skarbinski J, Njau JD, Goodman CA, Elling BF, Kahigwa E, Roberts J,
MacArthur J, Gutman J, Kabanywanyi A, Smith E, Somi M, Lyimo T, Mwita A,
Genton B, Tanner M, Mills A, Mshinda H, Bloland P, Abdulla S, Kachur SP: Routine
delivery of artemisinin-based combination treatment at fixed health facilities
reduces malaria prevalence in Tanzania: an observational study. Malar J 2012,
11:140.
8. Smithson P: Down down but not out. The impact of malaria control in Tanzania,
Ifakara Health Institute Spotlight; 2009.
9. Anonymous: Malaria Operational Plan (MOP), Tanzania, 2012, President’s Malaria
Initiative. ; 2012 [www.pmi.gov/countries/mops/fy12/tanzania_mop_fy12.pdf].
10. Anonymous: Malaria: Burden and Interventions. London: UKaid; 2012.
11. WHO: World Malaria Report 2009. Geneva: WHO; 2010.
12. Nyunt MM, Plowe CV: Pharmacologic advances in the global control and
treatment of malaria: combination therapy and resistance. Clin Pharmacol Ther
2007, 82:601–605.
13. Greenwood B, Marsh K, Snow R: Why do some African children develop severe
malaria? Parasitol Today 1991, 7:277–281.
14. D’Acremont V, Lengeler C, Mshinda H, Mtasiwa D, Tanner M, Genton B: Time to
move from presumptive malaria treatment to laboratory-confirmed diagnosis
and treatment in African children with fever. PLoS Med 2009, 6:e252.
15. McCombie S: Treatment seeking for malaria: a review of recent research.
Soc Sci Med 1996, 43:933–945.
16. Reyburn H, Mbatia R, Drakeley C, Carneiro I, Mwakasungula E, Mwerinde O,
Saganda K, Shao J, Kitua A, Olomi R, Cox J, Nkya WM, Lemnge M, Greenwood
BM, Riley EM: Overdiagnosis of malaria in patients with severe febrile illness in
Tanzania: a prospective study. BMJ 2004, 329:1212.
17. Alba S, Dillip A, Hetzel MW, Mayumana I, Mshana C, Makemba A, Alexander M,
Obrist B, Schulze A, Kessy F, Mshinda H, Lengeler C: Improvements in access to
malaria treatment in Tanzania following community, retail sector and health
facility interventions – a user perspective. Malar J 2010, 9:163.
18. Alonso PL, Bell D, Hanson K, Mendis K, Newman RD, de Savigny D, Schapira A,
Slutsker L, Tanner M, Teuscher T: A research agenda for malaria eradication:
health systems and operational research. PLoS Med 2011,
8:e1000397.
19. Paaijmans KP, Blanford S, Bell AS, Blanford JI, Read AF, Thomas MB: Influence of
climate on malaria transmission depends on daily temperature variation.
Proc Natl Acad Sci USA 2010, 107:15135–15139.
20. PMI: Malaria Operational Plan (MOP), TANZANIA, 2011. President’s Malaria Initiative;
2012.
21. Abdulla S, Schellenberg JA, Nathan R, Mukasa O, Marchant T, Smith T, Tanner M,
Lengeler C: Impact on malaria morbidity of a programme supplying
insecticide treated nets in children aged under 2 years in Tanzania:
community cross sectional study. BMJ 2001, 322:270–273.
22. Armstrong Schellenberg JR, Adam T, Mshinda H, Masanja H, Kabadi G, Mukasa O,
John T, Charles S, Nathan R, Wilczynska K, Mgalula L, Mbuya C, Mswia R, Manzi F,
de Savigny D, Schellenberg D, Victora C: Effectiveness and cost of facility-based
Integrated Management of Childhood Illness (IMCI) in Tanzania. Lancet 2004,
364:1583–1594.
23. Hetzel MW, Iteba N, Makemba A, Mshana C, Lengeler C, Obrist B, Schulze A,
Nathan R, Dillip A, Alba S, Mayumana I, Khatib R, Njau J, Mshinda H:
Understanding and improving access to prompt and effective malaria
treatment and care in rural Tanzania: the ACCESS Programme. Malar J 2007,
6:83.
24. Schellenberg D, Menendez C, Kahigwa E, Font F, Galindo C, Acosta C,
Schellenberg JA, Aponte JJ, Kimario J, Urassa H, Mshinda H, Tanner M, Alonso P:
African children with malaria in an area of intense Plasmodium falciparum
transmission: features on admission to the hospital and risk factors for death.
AmJTrop Med Hyg 1999, 61:431–438.
25. Schellenberg JA, Victora CG, Mushi A, de Savigny D, Schellenberg D, Mshinda H,
Bryce J: Inequities among the very poor: health care for children in rural
southern Tanzania. Lancet 2003, 361:561–566.
26. Schellenberg JR, Abdulla S, Minja H, Nathan R, Mukasa O, Marchant T, Mponda H,
Kikumbih N, Lyimo E, Manchester T, Tannes M, Lengeler C: KINET: a social
marketing programme of treated nets and net treatment for malaria control
in Tanzania, with evaluation of child health and long-term survival. Trans R
Soc Trop Med Hyg 1999, 93:225–231.
27. Schellenberg JR, Abdulla S, Nathan R, Mukasa O, Marchant TJ, Kikumbih N, Mushi
AK, Mponda H, Minja H, Mshinda H, Tanner M, Lengeler C: Effect of large-scale
social marketing of insecticide-treated nets on child survival in rural Tanzania.
Lancet 2001, 357:1241–1247.
28. Masanja IM, Selemani M, Amuri B, Kajungu D, Khatib R, Kachur SP, J S: Increased
use of malaria rapid diagnostic tests improves targeting of anti-malarial
treatment in rural Tanzania: implications for nationwide rollout of malaria
rapid diagnostic tests. Malar J 2012, 11:221.
29. Kakwani NC, Wagstaff A, van Doorslaer E: Socio-economic inequalities in health:
Measurement, computation and statistical inference. J Econometrics 1997,
77:87–104.
30. Gething P, Kirui V, Alegana V, Okiro E, A N, Snow R: Estimating the number of
paediatric fevers associated with malaria infection presenting to Africa’s
Public Health Sector in 2007. PLoS Med 2010, 7:e1000301.
31. Deressa W, Ali A, Enqusellassie F: Self-treatment of malaria in rural
communities, Butajira, southern Ethiopia. Bull World Health Organ 2003,
81:261–268.
32. National Bureau of Statistics (Ed): Tanzania HIV/AIDS and malaria indicator survey
2011–12; 2013.
33. Feachem R, Sabot O: A new global malaria eradication strategy. Lancet 2008,
371:1633–1635.
34. Tipke M, Louis V, Yé M, De Allegri M, Beiersmann C, Sié A, Mueller O, AJ A: Access
to malaria treatment in young children of rural Burkina Faso. Malar J 2009,
8:266.
35. Tarimo DS, Lwihula GK, Minjas JN, Bygbjerg IC:Mothers’ perceptions and
knowledge on childhood malaria in the holendemic Kibaha district, Tanzania:
implications for malaria control and the IMCI strategy. Trop Med Int Health
2000, 5:179–184.
36. Leahy TR, Malikiwi A, Cafferkey M, Butler KM: Imported childhood malaria: the
Dublin experience, 1999–2006. Ir J Med Sci 2009, 178:329–332.
37. Alba S, Hetzel MW, Goodman C, Dillip A, Liana J, Mshinda H, Lengeler C:
Improvements in access to malaria treatment in Tanzania after switch to
artemisinin combination therapy and the introduction of accredited drug
dispensing outlets - a provider perspective. Malar J 2010, 9:164.
38. de Savigny D, Mayombana C, Mwageni E, Masanja H, Minhaj A, Mkilindi Y, Mbuya
C, Kasale H, Reid G: Care-seeking patterns for fatal malaria in Tanzania. Malar J
2004, 3:27.
39. Tanner M, Vlassoff C: Treatment-seeking behaviour for malaria: a typology
based on endemicity and gender. Soc Sci Med 1998, 46:523–532.
40. Tanner M: Better Health for the Poor: A systems Approach. Basel: Swiss
Tropical Institute; 2004:94–103.
41. Tugwell P, de Savigny D, Hawker G, Robinson V: Applying clinical
epidemiological methods to health equity: the equity effectiveness loop.
BMJ 2006, 332:358–361.
42. Rutta E, Senauer K, Johnson K, Adeya G, Mbwasi R, Kimatta S, Sigonda M,
Alphonce E: Creating a new class of pharmaceutical services provider for
underserved areas: the Tanzania accredited drug dispensing outlet
experience. Prog Community Health Partnersh 2009, 3:145–153.
43. D'Acremont V, Lengeler C, Genton B: Reduction in the proportion of fevers
associated with Plasmodium falciparum parasitaemia in Africa: a systematic
review. Malar J 2010, 9:240.
doi:10.1186/1475-2875-12-155
Cite this article as: Khatib et al.: Access to artemisinin-based anti-
malarial treatment and its related factors in rural Tanzania. Malaria
Journal 2013 12:155.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Khatib et al. Malaria Journal 2013, 12:155 Page 8 of 8
http://www.malariajournal.com/content/12/1/155
